Published in Gene Therapy Weekly, March 10th, 2005
This compares with a net loss of $1,059,000, or $0.06 per basic and diluted share, for the same quarter 1 year ago.
"We are pleased at the progress made since the start of the last quarter and shortly after," stated Paul E. Freiman, president and chief executive officer. "Viprinex (ancrod), a late-stage reperfusion therapy for use in the treatment of ischemic stroke, received fast-track status from the U. S. Food and Drug Administration, a significant step forward in our pivotal...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.